TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy

被引：7

作者：

Alberto Henriquez-Hernandez, Luis ^{[1
]}

Fernandez Perez, Leandro ^{[1
]}

Gonzalez Hernandez, Ana ^{[2
]}

Cabrera de Leon, Antonio ^{[2
]}

Diaz-Chico, Bonifacio ^{[3
]}

Murias Rosales, A. ^{[4
]}

机构：

[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain

[2] Hosp Univ La Candelaria, Hosp La Candelaria, Res Unit, Santa Cruz de Tenerife 38010, Spain

[3] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain

[4] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain

来源：

CANCER EPIDEMIOLOGY | 2010年 / 34卷 / 04期

关键词：

Breast cancer; Adjuvant chemotherapy; Multifocal tumour; Polymorphism; PCR-RFLP; Risk factors; MTHFR; THYMIDYLATE SYNTHASE GENE; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK; FOLATE; DISEASE; METABOLISM; EXPRESSION; GENOTYPE; C3435T; DIET;

D O I：

10.1016/j.canep.2010.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy Results Observed allelic frequencies were TSER, (2)0 55 and (3)0 45, MTHFR C677T, (C) 065 and (T) 035: p53 Arg72Pro, (Arg) 076 and (Pro) 024, MDR1 C3435T, (C) 051 and (T) 0.49 MTHFR C677T was found to be a strong predictor of the presence of multifocal tumour (odds ratio, 4 1, 95% CI, 1 1-15 7, P = 0 035) Conclusion Our data indicate that breast cancer patients with the C/C variant may Present multifocal tumour most frequently (C) 2010 Elsevier Ltd All rights reserved

引用

下载

页码：490 / 493

页数：4

共 50 条

[31] CYP's and MDR1 gene polymorphisms in breast cancer: investigation of association with chemotherapy response
Goreva, O.
Seredina, T.
Grishanova, A.
FEBS JOURNAL, 2013, 280 : 622 - 622
[32] The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone
Al Hadithy, Asmar F. Y.
Wilffert, Bob
Bruggeman, Richard
Brouwers, Jacobus R. B. J.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (02): : 593 - 594
[33] Gene therapy for breast cancer. — review of clinical gene therapy trials for breast cancer and mdr1 gene therapy trial in cancer institute hospital
Takahashi S.
Ito Y.
Hatake K.
Sugimoto Y.
Breast Cancer, 2006, 13 (1) : 8 - 15
[34] Pharmacogenetics of cytochrome P450 enzymes and MDR1 in breast cancer patients treated with doxorubicin and cyclophosphamide
Lee, Johanne S.
Sludden, Julieann
Griffin, Melanie J.
Erb, Sharon
Verrill, Mark W.
Sumpter, Kate Anne
Boddy, Alan V.
CANCER RESEARCH, 2006, 66 (08)
[35] MDR1 gene expression in primary and advanced breast cancer
Yang, XW
Uziely, B
Groshen, S
Lukas, J
Israel, V
Russell, C
Dunnington, G
Formenti, S
Muggia, F
Press, MF
LABORATORY INVESTIGATION, 1999, 79 (03) : 271 - 280
[36] Expression of MDR1 and mutant p53 protein in hepatocellular carcinoma.
Grude, P
Conti, F
Louvel, A
Lecureur, V
Fardel, O
Calmus, Y
HEPATOLOGY, 1997, 26 (04) : 1314 - 1314
[37] Wild-type p53 binds to the human MDR1 promoter
Strauss, BE
Haas, M
FASEB JOURNAL, 1999, 13 (07): : A1480 - A1480
[38] Effect of MDR1 gene polymorphisms on mortality in paraquat intoxicated patients
Hak Jae Kim
Hyung-Ki Kim
Jun-Tack Kwon
Sun-hyo Lee
Sam el Park
Hyo-Wook Gil
Ho-yeon Song
Sae-yong Hong
Scientific Reports, 6
[39] Effect of MDR1 gene polymorphisms on mortality in paraquat intoxicated patients
Kim, Hak Jae
Kim, Hyung-Ki
Kwon, Jun-Tack
Lee, Sun-hyo
el Park, Sam
Gil, Hyo-Wook
Song, Ho-yeon
Hong, Sae-yong
SCIENTIFIC REPORTS, 2016, 6
[40] P53 and ERCC1 gene polymorphisms can predict the recurence risk of breast cancer
Kus, T.
Aktas, G.
Kalender, M. E.
Sevinc, A.
Camci, C.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →